Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Carisma Therapeutics Inc (CARM)

Carisma Therapeutics Inc (CARM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Carisma Announces Delisting from Nasdaq and SEC Deregistration PR Newswire - Fri Dec 5, 2025

PHILADELPHIA , Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends...

CARM : 0.0013 (+8.33%)
Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension Tipranks - Fri Oct 10, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Carisma Therapeutics...

CARM : 0.0013 (+8.33%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of Shareholders PR Newswire - Wed Jul 16, 2025

NEW YORK , July 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CARM : 0.0013 (+8.33%)
HLGN : 1.7000 (+2.10%)
NVEE : 22.56 (+0.49%)
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases GlobeNewswire - Mon Jun 23, 2025

CARM : 0.0013 (+8.33%)
OCGN : 1.3750 (-2.48%)
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases GlobeNewswire - Mon Jun 23, 2025

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy...

CARM : 0.0013 (+8.33%)
OCGN : 1.3750 (-2.48%)
Carisma Therapeutics to Present at Upcoming Investor Conferences PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...

CARM : 0.0013 (+8.33%)
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...

CARM : 0.0013 (+8.33%)
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 PR Newswire - Thu Aug 24, 2023

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...

CARM : 0.0013 (+8.33%)
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors PR Newswire - Wed Jun 28, 2023

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...

CARM : 0.0013 (+8.33%)
Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes PR Newswire - Mon Jun 26, 2023

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...

CARM : 0.0013 (+8.33%)

Barchart Exclusives

Nvidia’s Earnings Blowout Is Good News and Bad News for Retirement Investors Barchart - 1 minute ago
The path to a continued bull market runs through NVDA. Without this stock’s price rising, it is hard to imagine a market rally into year end. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.